Although our results suggest that SS, per se, is not associated with an increased frequency of activating point mutations in the STAT3, we think that a study of STAT3 mutations in a cohort of pSS patients without sign of T-LGL leukemia would clarify this issue. This evidence concerns the gene STAT3 and leukemia.